Caribou Biosciences
CRBU1.4603.31% ( -0.050 )
Caribou Biosciences (CRBU)
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical compa...
- Open
- 1.530
- High
- 1.530
- Low
- 1.430
- Prev. Close
- 1.510
- Volume
- 1.13M
- Turnover
- 1.64M
- Avg Price
- 1.455
- Bid/Ask Ratio
- --
- Amplitude
- 6.62%
- 52wk High
- 3.535
- Volume Ratio
- 0.99
- Turnover Ratio
- 1.19%
Caribou Biosciences Analyst Rating
View MoreForecast & Rating
Jul 6, 2026Price forecast
$12.00721.92%
Forecast & RatingStrong buy
7analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 22 at 04:18 AM
Restructuring Global Liquidity: Structural Opportunities from US Defense to Yield-Bearing ETFs
- PUBT · Jun 29 at 07:02 AM
Caribou Biosciences CEO joins H.C. Wainwright cell therapy conference fireside chat
- PUBT · Jun 18 at 03:03 PM
Caribou Biosciences shareholders reject officer exculpation charter amendment at annual meeting
- Tip Ranks · Jun 16 at 05:16 AM
Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11
- Tip Ranks · Jun 11 at 07:25 PM
Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data
- Tip Ranks · Jun 11 at 07:19 PM
Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
